The global biotechnology instrumentation market is anticipated to witness lucrative growth over the forecast period. The key driver of the market is the rising need of biotechnological tools in biotech, pharmaceutical, and other related industries. Pharmaceutical companies are expected to improve and enhance their R&D leading to the rising need for biotechnological instruments for the purpose of experimentation, testing, and analysis. New product development and investigation of existing drugs for better or advanced therapeutic activity are also expected to fuel the growth of the market. Advances in the quality of instruments and improving throughput capacity are expected to further propel the growth of the market. Other drivers such as increasing government funding, rising environmental monitoring, and safety concerns and augmenting applications of the biotechnology instruments in applied markets are expected to boost the market. Post the Human Genome Project completion, the true strengths of biotechnological instruments have been witnessed and unleashed, thereby, expecting to help boost the growth of the market.
The biotechnology instrumentation market can be segmented according to technology and end users. On the basis of technology the market is segmented into electrophoresis, immunoassay, chromatography (especially HPLC (High-Performance Liquid Chromatography), imaging, microarray technology, laboratory automation, and mass spectroscopy. Electrophoresis is further segmented into gel and capillary electrophoresis. Immunoassay is further subdivided into enzyme, radio, fluorescence, and chemiluminescence immunoassays. The chromatography segment is further subdivided into liquid and gas chromatography. Liquid chromatography is preferred over gas owing to excessive reagents availability and procedural ease. Microarray technology is further segmented into DNA, protein, cell, and tissue. Mass spectroscopy is further segmented into mass, molecular and atomic spectroscopy. Imaging dominates the biotechnology instrumentation market based on technology with the largest share, followed by electrophoresis. The dominance of imaging is expected to sustain during the forecast period due to the varied application of the instrumentation. On the basis of end users, the market is broadly classified into three categories namely; pharmaceutical companies, research institutes, and biotech companies. Pharmaceutical and biotechnological companies held a maximum share of the market and are expected to retain them over the forecast period.
Regionally, the market is divided into five areas, namely; North America, Latin America, Europe, Asia Pacific, and MEA (the Middle East and Africa). North America dominated the biotechnology instrumentation market and is expected to maintain dominance over the forecast period. The drivers for this dominance are abundant R&D activities and excessive government spending on the development of the market. The initiation of the Human Genome Project by North America is a major contributor to the dominance, thereby anticipating the increasing and diversified application of biotechnology instruments in the region. Europe follows North America in terms of market share and is expected to retain its position over the forecast period. Emerging regions for the market are expected to be China, India, Singapore, and Brazil thereby promoting the fastest growth in Asia Pacific followed by Latin America. The booming growth in the regions is anticipated due to rising attractiveness for companies engaged in the development and distribution of biotechnology instruments. A number of other factors such as enhancing development by large pharmaceutical and biotech companies, increasing government support and funding to develop the pharmaceutical industry, and a growing number of Contract Research Organizations (CROs) in developing nations are expected to offer new growth avenues in this region.
Key players in biotechnology instrumentation market are Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Spinco biotech Ltd. (India), Shimadzu Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Eppendorf (U.S.), Bruker Corporation (U.S.), Sigma Aldrich (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and Waters Corporation (U.S.). Expansion and opening of subsidiaries in new regions by existing companies are expected to boost the growth of the market during the forecast period. Technological upgrades and innovation such as new technique development, increasing efficiency, improving reagent combinations, and utilization by the key players is further expected to fuel the growth of the market.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.